Adrian Newman-Tancredi, PhD, DSc, will present at the forthcoming Encéphale Congress to be held January 18-20, 2017 in Paris, France. Dr. Newman-Tancredi has been invited in his capacity as Chief Scientific Officer of Neurolixis to give a lecture on emerging drug discovery concepts for the development of novel antidepressants.

Dr. Newman-Tancredi's presentation will be part of the plenary session entitled "Psychopharmacology in the third millennium" on Wednesday 18 January 2017 and will focus on prospects for improved treatment of depressive disorders using highly selective 'biased agonists' targeting cortical serotonin 5-HT1A receptors.  

For full details of the Encéphale Congress program see the meeting website.

15e Congrès de l'Encéphale